News
Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback